Analysts Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Price Target at $44.89

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been given a consensus rating of “Hold” by the nine ratings firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $44.89.

Several research analysts have commented on the stock. StockNews.com cut shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. JMP Securities decreased their target price on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. Finally, Truist Financial decreased their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research report on Friday, March 1st.

Institutional Trading of Integra LifeSciences

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after buying an additional 72,294 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of Integra LifeSciences by 40.1% in the fourth quarter. Capital Research Global Investors now owns 4,297,326 shares of the life sciences company’s stock valued at $187,149,000 after purchasing an additional 1,228,996 shares in the last quarter. Cooke & Bieler LP boosted its position in shares of Integra LifeSciences by 4.4% in the fourth quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after buying an additional 120,410 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Integra LifeSciences by 4.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock valued at $70,340,000 after buying an additional 63,323 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Integra LifeSciences by 19.5% in the 3rd quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after acquiring an additional 238,816 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $28.34 on Friday. The firm has a market cap of $2.23 billion, a PE ratio of 34.14, a price-to-earnings-growth ratio of 0.85 and a beta of 1.12. The firm’s 50-day simple moving average is $35.34 and its 200-day simple moving average is $38.77. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 1 year low of $27.18 and a 1 year high of $56.21.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The business had revenue of $397.00 million for the quarter, compared to analyst estimates of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the company earned $0.94 EPS. Equities analysts forecast that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.